APC-811
Isomangiferin

Cat. No.

APC-811

CAS No.

24699-16-9

MF

C19H18O11

MW

422.342

Isomangiferin is an xanthone C-glucoside,an effective VEGFR-2 kinase inhibitor.
Package Specification Stock Quantity Request Quote
20mg 98% In Stock
Add
100mg 98% In Stock
Add
1g 98% In Stock
Add
Technical Service
Need help? Our team of experienced experts is here for you with full support.
86-28-85159085
info@aktin.com
Inquiry
Technical Data
Description
Storage and Shipping
References
Product Name
Isomangiferin
CAS No.
24699-16-9
MF
C19H18O11
MW
422.342
Specification
98%
Research Area
Neuroprotection, anti-anxiety/depression, anti-liver fibrosis and liver protection
Description
Isomangiferin is an xanthone C-glucoside,an effective VEGFR-2 kinase inhibitor.
Packing: 10mg, 20mg, 50mg, 100mg, 500mg, 1g, 5g, 10g
Availability: In stock
Documents
Certificate of Analysis (COA), Specification Sheet, HPLC, 1HNMR, 13CNMR, IR, MS, Safety Data Sheet (SDS/MSDS) etc.
Storage and Shipping
Store under frozen or refrigerated conditions, keep away from strong light and heat.
References
[1]. Zheng MS, et al. Antiviral effect of mangiferin and isomangiferin on herpes simplex virus. Chin Med J (Engl). 1990 Feb;103(2):160-5.
[2]. Ishaque M, et al. Xanthone C-glycosides isomers purified from Dryopteris ramosa (Hope) C. Chr. with bactericidal and cytotoxic prospects. Saudi J Biol Sci. 2022 Feb;29(2):1191-1196.
[3]. Gao B, et al. Isomangiferin promotes the migration and osteogenic differentiation of rat bone marrow mesenchymal stem cells. Open Life Sci. 2024 Jul 20;19(1):20220884. doi: 10.1515/biol-2022-0884. PMID: 39035458; PMCID: PMC11259999.
[4]. Yue S, et al. Isomangiferin Attenuates Renal Injury in Diabetic Mice via Inhibiting Inflammation. Diabetes Metab Syndr Obes. 2020 Nov 10;13:4273-4280.
[5]. Wang B, et al. Isomangiferin, a Novel Potent Vascular Endothelial Growth Factor Receptor 2 Kinase Inhibitor, Suppresses Breast Cancer Growth, Metastasis and Angiogenesis. J Breast Cancer. 2018 Mar;21(1):11-20.,
Disclaimer
This product is intended solely for scientific research or regulatory filing purposes. We do not provide products or services to individuals, please strictly comply with all applicable laws, regulations, and the committed use. Use for any other purpose is strictly prohibited.
Related Products
APC-1828
Eritadenine

CAS No.: 23918-98-1

MF: C9H11N5O4

View Details
APC-1827
Isobutyrylshikonin

CAS No.:52438-12-7

MF:C20H22O6

View Details
APC-1823
SO1861 (C28 sugar-chain positional isomer)

CAS No.:N/A

MF:C83H129O46

View Details
APC-1822
Bromocriptine mesylate

CAS No.:22260-51-1

MF:C32H40BrN5O5.CH4O3S

View Details
APC-1821
Cephaeline hydrochloride

CAS No.:3738-70-3

MF:C28H38N2O4.ClH

View Details
APC-1820
8-Feruloylharpagide

CAS No.:221003-20-9

MF:C25H32O13

View Details
APC-1819
6''-O-(p-coumaroyl)procumbide

CAS No.:87686-76-8

MF:C24H28O12

View Details
APC-1818
6′′-O-(p-Coumaroyl)harpagide

CAS No.:133561-42-9

MF:C24H30O12

View Details
APC-1817
Falcarinol

CAS No.:21852-80-2

MF:C17H24O

View Details
APC-1816
Dehydrotomatine

CAS No.:157604-98-3

MF:C50H81NO21

View Details
* Some statements have not been evaluated by national authorities.
* Some products are not intended to diagnose, treat, cure, or prevent any disease.
* For literature supporting, please contact us directly.
Cart
TotalProducts
Request Quote
  • China
  • Afghanistan
  • Albania
  • Algeria
  • Andorra
  • Angola
  • Antigua and Barbuda
  • Argentina
  • Armenia
  • Australia
  • Austria
  • Azerbaijan
  • Bahamas
  • Bahrain
  • Bangladesh
  • Barbados
  • Belarus
  • Belgium
  • Belize
  • Benin
  • Bhutan
  • Bolivia
  • Bosnia and Herzegovina
  • Botswana
  • Brazil
  • Brunei
  • Bulgaria
  • Burkina Faso
  • Burundi
  • Cambodia
  • Cameroon
  • Canada
  • Cape Verde
  • Central African Republic
  • Chad
  • Chile
  • Colombia
  • Comoros
  • Congo (Brazzaville)
  • Congo (Kinshasa)
  • Cook Islands
  • Costa Rica
  • Côte d'Ivoire
  • Croatia
  • Cuba
  • Cyprus
  • Czech Republic
  • Denmark
  • Djibouti
  • Dominica
  • Dominican Republic
  • East Timor (Timor-Leste)
  • Ecuador
  • Egypt
  • El Salvador
  • Equatorial Guinea
  • Eritrea
  • Estonia
  • Eswatini
  • Ethiopia
  • Fiji
  • Finland
  • France
  • Gabon
  • Gambia
  • Georgia
  • Germany
  • Ghana
  • Greece
  • Grenada
  • Guatemala
  • Guinea
  • Guinea-Bissau
  • Guyana
  • Haiti
  • Honduras
  • Hungary
  • Iceland
  • India
  • Indonesia
  • Iran
  • Iraq
  • Ireland
  • Israel
  • Italy
  • Jamaica
  • Japan
  • Jordan
  • Kazakhstan
  • Kenya
  • Kiribati
  • South Korea
  • Kuwait
  • Kyrgyzstan
  • Laos
  • Latvia
  • Lebanon
  • Lesotho
  • Liberia
  • Libya
  • Liechtenstein
  • Lithuania
  • Luxembourg
  • Madagascar
  • Malawi
  • Malaysia
  • Maldives
  • Mali
  • Malta
  • Marshall Islands
  • Mauritania
  • Mauritius
  • Mexico
  • Micronesia
  • Moldova
  • Monaco
  • Mongolia
  • Montenegro
  • Morocco
  • Mozambique
  • Myanmar (Burma)
  • Namibia
  • Nauru
  • Nepal
  • Netherlands
  • New Zealand
  • Nicaragua
  • Niger
  • Nigeria
  • North Macedonia
  • Norway
  • Oman
  • Pakistan
  • Palau
  • Panama
  • Papua New Guinea
  • Paraguay
  • Peru
  • Philippines
  • Poland
  • Portugal
  • Qatar
  • Romania
  • Russia
  • Rwanda
  • Saint Kitts and Nevis
  • Saint Lucia
  • Saint Vincent and the Grenadines
  • Samoa
  • San Marino
  • Sao Tome and Principe
  • Saudi Arabia
  • Senegal
  • Serbia
  • Seychelles
  • Sierra Leone
  • Singapore
  • Slovakia
  • Slovenia
  • Solomon Islands
  • Somalia
  • South Africa
  • Spain
  • Sri Lanka
  • Sudan
  • South Sudan
  • Suriname
  • Sweden
  • Switzerland
  • Syria
  • Tajikistan
  • Tanzania
  • Thailand
  • Togo
  • Tonga
  • Trinidad and Tobago
  • Tunisia
  • Turkey
  • Turkmenistan
  • Tuvalu
  • Uganda
  • Ukraine
  • United Arab Emirates (UAE)
  • United Kingdom (UK)
  • United States (US)
  • Uruguay
  • Uzbekistan
  • Vanuatu
  • Vatican City
  • Venezuela
  • Vietnam
  • Yemen
  • Zambia
  • Zimbabwe
  • Beijing-Beijing
  • Tianjin-Tianjin
  • Hebei-Shijiazhuang
  • Shanxi-Taiyuan
  • Inner Mongolia-Hohhot
  • Liaoning-Shenyang
  • Jilin-Changchun
  • Heilongjiang-Harbin
  • Shanghai-Shanghai
  • Jiangsu-Nanjing
  • Zhejiang-Hangzhou
  • Anhui-Hefei
  • Fujian-Fuzhou
  • Jiangxi-Nanchang
  • Shandong-Jinan
  • Henan-Zhengzhou
  • Hubei-Wuhan
  • Hunan-Changsha
  • Guangdong-Guangzhou
  • Guangxi-Nanning
  • Hainan-Haikou
  • Chongqing-Chongqing
  • Sichuan-Chengdu
  • Guizhou-Guiyang
  • Yunnan-Kunming
  • Tibet-Lhasa
  • Shaanxi-Xi'an
  • Gansu-Lanzhou
  • Qinghai-Xining
  • Ningxia-Yinchuan
  • Xinjiang-Urumqi
  • Hong Kong-Hong Kong
  • Macao-Macao
  • Taiwan-Taipei